Newsletter
Pharma stocks are under pressure after US President Donald Trump signed an order that could impose tariffs of up to 100% on certain imported drugs.
Market mood: Sun Pharma, IPCA Labs, and Ajanta Pharma slipped on the back of this development.
The deets: the US is targeting patented medicines to reduce reliance on foreign pharma supplies, calling it a national security move.
The White House said the goal behind these tariffs is to cut reliance on overseas pharmaceutical supplies.
Companies that agree to US pricing rules and shift manufacturing locally will face zero tariffs. Those that don’t could see tariffs start at 20% and rise to 100% over four years.
The India impact: short-term impact is limited. Indian firms mainly export generic drugs, which are exempt, so business should continue as usual for now.
But in the long run, things could change. Higher tariffs on patented drugs and ingredients may push global companies to move production to the US, potentially affecting India’s role in the global pharma supply chain.
